Skip Navigation
Skip to contents

Diabetes Metab J : Diabetes & Metabolism Journal

Search
OPEN ACCESS

Author index

Page Path
HOME > Browse > Author index
Search
Dae Ho Lee  (Lee DH) 9 Articles
Metabolic Risk/Epidemiology
Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease
Seung Joon Choi, Seong Min Kim, Yun Soo Kim, Oh Sang Kwon, Seung Kak Shin, Kyoung Kon Kim, Kiyoung Lee, Ie Byung Park, Cheol Soo Choi, Dong Hae Chung, Jaehun Jung, MunYoung Paek, Dae Ho Lee
Diabetes Metab J. 2021;45(5):739-752.   Published online October 28, 2020
DOI: https://doi.org/10.4093/dmj.2020.0137
  • 8,580 View
  • 218 Download
  • 13 Web of Science
  • 15 Crossref
Graphical AbstractGraphical Abstract AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
Several noninvasive tools are available for the assessment of nonalcoholic fatty liver disease (NAFLD) including clinical and blood biomarkers, transient elastography (TE), and magnetic resonance imaging (MRI) techniques, such as proton density fat fraction (MRI-PDFF) and magnetic resonance elastography (MRE). In the present study, we aimed to evaluate whether magnetic resonance (MR)-based examinations better discriminate the pathophysiologic features and fibrosis progression in NAFLD than other noninvasive methods.
Methods
A total of 133 subjects (31 healthy volunteers and 102 patients with NAFLD) were subjected to clinical and noninvasive NAFLD evaluation, with additional liver biopsy in some patients (n=54).
Results
MRI-PDFF correlated far better with hepatic fat measured by MR spectroscopy (r=0.978, P<0.001) than with the TE controlled attenuation parameter (CAP) (r=0.727, P<0.001). In addition, MRI-PDFF showed stronger correlations with various pathophysiologic parameters for cellular injury, glucose and lipid metabolism, and inflammation, than the TE-CAP. The MRI-PDFF and TE-CAP cutoff levels associated with abnormal elevation of serum alanine aminotransferase were 9.9% and 270 dB/m, respectively. The MRE liver stiffness measurement (LSM) showed stronger correlations with liver enzymes, platelets, complement component 3, several clinical fibrosis scores, and the enhanced liver fibrosis (ELF) score than the TE-LSM. In an analysis of only biopsied patients, MRE performed better in discriminating advanced fibrosis with a cutoff value of 3.9 kPa than the TE (cutoff 8.1 kPa) and ELF test (cutoff 9.2 kPa).
Conclusion
Our results suggest that MRI-based assessment of NAFLD is the best non-invasive tool that captures the histologic, pathophysiologic and metabolic features of the disease.

Citations

Citations to this article as recorded by  
  • A Novel Score Based on Controlled Attenuation Parameter Accurately Predicts Hepatic Steatosis in Individuals With Metabolic Dysfunction Associated Steatotic Liver Disease: A Derivation and Independent Validation Study
    Zi-Ming An, Qiao-Hong Liu, Xin-Jian Ye, Qian Zhang, Hua-Fu Pei, Xin Xin, Jie Yuan, Qian Huang, Kun Liu, Fang Lu, Zhi-Han Yan, Yu Zhao, Yi-Yang Hu, Ming-Hua Zheng, Qin Feng
    Clinical and Translational Gastroenterology.2024; 15(3): e00680.     CrossRef
  • Imaging Methods Applicable in the Diagnostics of Alzheimer’s Disease, Considering the Involvement of Insulin Resistance
    Petra Hnilicova, Ema Kantorova, Stanislav Sutovsky, Milan Grofik, Kamil Zelenak, Egon Kurca, Norbert Zilka, Petra Parvanovova, Martin Kolisek
    International Journal of Molecular Sciences.2023; 24(4): 3325.     CrossRef
  • Polyunsaturated and Saturated Oxylipin Plasma Levels Allow Monitoring the Non-Alcoholic Fatty Liver Disease Progression to Severe Stages
    Miguel D. Ferrer, Clara Reynés, Margalida Monserrat-Mesquida, Magdalena Quetglas-Llabrés, Cristina Bouzas, Silvia García, David Mateos, Miguel Casares, Cristina Gómez, Lucía Ugarriza, Josep A. Tur, Antoni Sureda, Antoni Pons
    Antioxidants.2023; 12(3): 711.     CrossRef
  • An individual patient data meta-analysis to determine cut-offs for and confounders of NAFLD-fibrosis staging with magnetic resonance elastography
    Jia-xu Liang, Javier Ampuero, Hao Niu, Kento Imajo, Mazen Noureddin, Jaideep Behari, Dae Ho Lee, Richard L. Ehman, Fredrik Rorsman, Johan Vessby, Juan R. Lacalle, Ferenc E. Mózes, Michael Pavlides, Quentin M. Anstee, Stephen A. Harrison, Javier Castell, R
    Journal of Hepatology.2023; 79(3): 592.     CrossRef
  • Relationship between controlled attenuated parameter and magnetic resonance imaging–proton density fat fraction for evaluating hepatic steatosis in patients with NAFLD
    Ziming An, Qiaohong Liu, Wenli Zeng, Yan Wang, Qian Zhang, Huafu Pei, Xin Xin, Shuohui Yang, Fang Lu, Yu Zhao, Yiyang Hu, Qin Feng
    Hepatology Communications.2022; 6(8): 1975.     CrossRef
  • Noninvasive imaging of hepatic dysfunction: A state-of-the-art review
    Ting Duan, Han-Yu Jiang, Wen-Wu Ling, Bin Song
    World Journal of Gastroenterology.2022; 28(16): 1625.     CrossRef
  • Diagnosis and Pathogenesis of Sarcopenia in Chronic Liver Disease Using Liver Magnetic Resonance Imaging
    Atsushi Nakamura, Tsubasa Yoshimura, Tomomi Sato, Takeshi Ichikawa
    Cureus.2022;[Epub]     CrossRef
  • Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
    Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
    International Journal of Molecular Sciences.2022; 23(9): 5035.     CrossRef
  • Contribution of a genetic risk score to ethnic differences in fatty liver disease
    Maddie J. Kubiliun, Jonathan C. Cohen, Helen H. Hobbs, Julia Kozlitina
    Liver International.2022; 42(10): 2227.     CrossRef
  • Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
    Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
    Biomedicines.2022; 10(7): 1669.     CrossRef
  • Updated S2k Clinical Practice Guideline on Non-alcoholic Fatty Liver Disease (NAFLD) issued by the German Society of Gastroenterology, Digestive and Metabolic Diseases (DGVS) – April 2022 – AWMF Registration No.: 021–025

    Zeitschrift für Gastroenterologie.2022; 60(09): e733.     CrossRef
  • Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
    E. Roeb, A. Canbay, H. Bantel, J. Bojunga, J. de Laffolie, M. Demir, U. W. Denzer, A. Geier, W. P. Hofmann, C. Hudert, T. Karlas, M. Krawczyk, T. Longerich, T. Luedde, M. Roden, J. Schattenberg, M. Sterneck, A. Tannapfel, P. Lorenz, F. Tacke
    Zeitschrift für Gastroenterologie.2022; 60(09): 1346.     CrossRef
  • Ultrasound Methods for the Assessment of Liver Steatosis: A Critical Appraisal
    Dorotea Bozic, Kristian Podrug, Ivana Mikolasevic, Ivica Grgurevic
    Diagnostics.2022; 12(10): 2287.     CrossRef
  • Significance of liver fat loss in chronic liver disease: Usefulness of hepatic proton density fat fraction measurement by magnetic resonance imaging in evaluating malnutrition
    Atsushi Nakamura, Haruka Okada, Tsubasa Yoshimura, Manami Deguchi, Yuei Hosokawa, Tomomi Satoh, Takeshi Ichikawa, Keiji Okuyama, Yoshihiro Yoshioka, Hitoshi Asakura
    Kanzo.2021; 62(9): 525.     CrossRef
  • Screening for nonalcoholic fatty liver disease-when, who and how?
    Christoph G Dietrich, Monika Rau, Andreas Geier
    World Journal of Gastroenterology.2021; 27(35): 5803.     CrossRef
Guideline/Fact Sheet
Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee, Korean Diabetes Association (KDA) Fatty Liver Research Group
Diabetes Metab J. 2020;44(3):382-401.   Published online May 11, 2020
DOI: https://doi.org/10.4093/dmj.2020.0010
  • 12,222 View
  • 335 Download
  • 42 Web of Science
  • 42 Crossref
AbstractAbstract PDFPubReader   

This clinical practice position statement, a product of the Fatty Liver Research Group of the Korean Diabetes Association, proposes recommendations for the diagnosis, progression and/or severity assessment, management, and follow-up of non-alcoholic fatty liver disease (NAFLD) in patients with type 2 diabetes mellitus (T2DM). Patients with both T2DM and NAFLD have an increased risk of non-alcoholic steatohepatitis (NASH) and fibrosis and a higher risk of cardiovascular diseases and diabetic complications compared to those without NAFLD. With regards to the evaluation of patients with T2DM and NAFLD, ultrasonography-based stepwise approaches using noninvasive biomarker models such as fibrosis-4 or the NAFLD fibrosis score as well as imaging studies such as vibration-controlled transient elastography with controlled attenuation parameter or magnetic resonance imaging-proton density fat fraction are recommended. After the diagnosis of NAFLD, the stage of fibrosis needs to be assessed appropriately. For management, weight reduction achieved by lifestyle modification has proven beneficial and is recommended in combination with antidiabetic agent(s). Evidence that some antidiabetic agents improve NAFLD/NASH with fibrosis in patients with T2DM is emerging. However, there are currently no definite pharmacologic treatments for NAFLD in patients with T2DM. For specific cases, bariatric surgery may be an option if indicated.

Citations

Citations to this article as recorded by  
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; : e076388.     CrossRef
  • Risk Scores for Prediction of Major Cardiovascular Events in Non-Alcoholic Fatty Liver Disease: A No Man’s Land?
    Liliana Gheorghe, Roxana Nemteanu, Andreea Clim, Gina Eosefina Botnariu, Irina Iuliana Costache, Alina Plesa
    Life.2023; 13(4): 857.     CrossRef
  • Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
    Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
    Metabolism.2023; 145: 155612.     CrossRef
  • Association between fatty liver index and risk of end-stage renal disease stratified by kidney function in patients with type 2 diabetes: A nationwide population-based study
    Goh Eun Chung, Kyungdo Han, Kyu-Na Lee, Jung Ho Bae, Sun Young Yang, Su-Yeon Choi, Jeong Yoon Yim, Nam Ju Heo
    Diabetes & Metabolism.2023; 49(4): 101454.     CrossRef
  • Comparison of glucagon-like peptide-1 receptor agonists and thiazolidinediones on treating nonalcoholic fatty liver disease: A network meta-analysis
    Min Jeong Park, Hayeon Kim, Myeong Gyu Kim, Kyungim Kim
    Clinical and Molecular Hepatology.2023; 29(3): 693.     CrossRef
  • Histological analysis of hypoglycemic agents on liver fibrosis in patients with non-alcoholic fatty liver disease: a systematic review
    Qingxing Xie, Xiaohui Pan, Xinyue Zhang, Jinfang Ma, Ge Peng, Nanwei Tong
    Chinese Medical Journal.2023; 136(16): 2014.     CrossRef
  • Hepatotropc effects of glucose-lowering drugs: non-alcoholic fatty liver disease in focus
    E. V. Uzhakova, Z. E. Zshanko, E. N. Smirnova
    Experimental and Clinical Gastroenterology.2023; (6): 121.     CrossRef
  • Complementary effects of dapagliflozin and lobeglitazone on metabolism in a diet-induced obese mouse model
    Yun Kyung Lee, Tae Jung Oh, Ji In Lee, Bo Yoon Choi, Hyen Chung Cho, Hak Chul Jang, Sung Hee Choi
    European Journal of Pharmacology.2023; 957: 175946.     CrossRef
  • Hepatic T-cell senescence and exhaustion are implicated in the progression of fatty liver disease in patients with type 2 diabetes and mouse model with nonalcoholic steatohepatitis
    Byeong Chang Sim, Yea Eun Kang, Sun Kyoung You, Seong Eun Lee, Ha Thi Nga, Ho Yeop Lee, Thi Linh Nguyen, Ji Sun Moon, Jingwen Tian, Hyo Ju Jang, Jeong Eun Lee, Hyon-Seung Yi
    Cell Death & Disease.2023;[Epub]     CrossRef
  • 2023 Clinical Practice Guidelines for Diabetes Mellitus of the Korean Diabetes Association
    Jong Han Choi, Kyung Ae Lee, Joon Ho Moon, Suk Chon, Dae Jung Kim, Hyun Jin Kim, Nan Hee Kim, Ji A Seo, Mee Kyoung Kim, Jeong Hyun Lim, YoonJu Song, Ye Seul Yang, Jae Hyeon Kim, You-Bin Lee, Junghyun Noh, Kyu Yeon Hur, Jong Suk Park, Sang Youl Rhee, Hae J
    Diabetes & Metabolism Journal.2023; 47(5): 575.     CrossRef
  • A combined extract containing Schisandra chinensis (SCE) reduced hepatic triglyceride accumulation in rats fed a high-sucrose diet
    Haneul Lee, Eun Young Kang, Joowon Lee, Yejin Kim, Sumin Kang, Hayoon Kim, Hyun Kyung Kim, Gyoungok Gang, Sang-gil Lee, Cao Lei, Gwang-woong Go
    Food Science and Biotechnology.2023;[Epub]     CrossRef
  • Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
    Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
    Scientific Reports.2023;[Epub]     CrossRef
  • Stratification by obesity class, rather than age, can identify a higher percent of children at risk for non‐alcoholic fatty liver disease and metabolic dysfunction
    Aurelia Radulescu, Adam J. Dugan, Mary Killian, Suzanna L. Attia, Marialena Mouzaki, George J. Fuchs, Rohit Kohli, Henrietta Bada, Philip A. Kern, Samir Softic
    Pediatric Obesity.2022;[Epub]     CrossRef
  • Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
    Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Diabetes & Metabolism Journal.2022; 46(1): 104.     CrossRef
  • Dulaglutide Ameliorates Palmitic Acid-Induced Hepatic Steatosis by Activating FAM3A Signaling Pathway
    Jinmi Lee, Seok-Woo Hong, Min-Jeong Kim, Sun Joon Moon, Hyemi Kwon, Se Eun Park, Eun-Jung Rhee, Won-Young Lee
    Endocrinology and Metabolism.2022; 37(1): 74.     CrossRef
  • State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
    Yongin Cho, Yong-ho Lee
    Endocrinology and Metabolism.2022; 37(1): 38.     CrossRef
  • Ezetimibe combination therapy with statin for non-alcoholic fatty liver disease: an open-label randomized controlled trial (ESSENTIAL study)
    Yongin Cho, Hyungjin Rhee, Young-eun Kim, Minyoung Lee, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Jin-Young Choi, Yong-ho Lee
    BMC Medicine.2022;[Epub]     CrossRef
  • Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
    Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
    Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
  • Anti-Obesity and Anti-Hyperglycemic Effects of Meretrix lusoria Protamex Hydrolysate in ob/ob Mice
    Min Ju Kim, Ramakrishna Chilakala, Hee Geun Jo, Seung-Jae Lee, Dong-Sung Lee, Sun Hee Cheong
    International Journal of Molecular Sciences.2022; 23(7): 4015.     CrossRef
  • The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
    Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Cumulative Exposure to High γ-Glutamyl Transferase Level and Risk of Diabetes: A Nationwide Population-Based Study
    Ji-Yeon Park, Kyungdo Han, Hun-Sung Kim, Jae-Hyoung Cho, Kun-Ho Yoon, Mee Kyoung Kim, Seung-Hwan Lee
    Endocrinology and Metabolism.2022; 37(2): 272.     CrossRef
  • SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease
    Jun Sung Moon, Jun Hwa Hong, Yong Jin Jung, Ele Ferrannini, Michael A. Nauck, Soo Lim
    Trends in Endocrinology & Metabolism.2022; 33(6): 424.     CrossRef
  • Plasma Aldo-Keto Reductase Family 1 Member B10 as a Biomarker Performs Well in the Diagnosis of Nonalcoholic Steatohepatitis and Fibrosis
    Aron Park, Seung Joon Choi, Sungjin Park, Seong Min Kim, Hye Eun Lee, Minjae Joo, Kyoung Kon Kim, Doojin Kim, Dong Hae Chung, Jae Been Im, Jaehun Jung, Seung Kak Shin, Byung-Chul Oh, Cheolsoo Choi, Seungyoon Nam, Dae Ho Lee
    International Journal of Molecular Sciences.2022; 23(9): 5035.     CrossRef
  • Chinese Herbal Medicine for Type 2 Diabetes Mellitus With Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Sihan Peng, Lu Liu, Ziyan Xie, Xiyu Zhang, Chunguang Xie, Sha Ye, Xiangeng Zhang, Xiaoli Liang, Hongyan Wang, Ya Liu
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Non-alcoholic fatty liver disease and sarcopenia is associated with the risk of albuminuria independent of insulin resistance, and obesity
    Eugene Han, Mi Kyung Kim, Seung-Soon Im, Byoung Kuk Jang, Hye Soon Kim
    Journal of Diabetes and its Complications.2022; 36(8): 108253.     CrossRef
  • Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
    Eun-Jung Rhee
    Endocrinology and Metabolism.2022; 37(3): 415.     CrossRef
  • Plasma Metabolomics and Machine Learning-Driven Novel Diagnostic Signature for Non-Alcoholic Steatohepatitis
    Moongi Ji, Yunju Jo, Seung Joon Choi, Seong Min Kim, Kyoung Kon Kim, Byung-Chul Oh, Dongryeol Ryu, Man-Jeong Paik, Dae Ho Lee
    Biomedicines.2022; 10(7): 1669.     CrossRef
  • Association Between DPP4 Inhibitor Use and the Incidence of Cirrhosis, ESRD, and Some Cancers in Patients With Diabetes
    Yewon Na, Soo Wan Kim, Ie Byung Park, Soo Jung Choi, Seungyoon Nam, Jaehun Jung, Dae Ho Lee
    The Journal of Clinical Endocrinology & Metabolism.2022; 107(11): 3022.     CrossRef
  • Nonalcoholic fatty liver disease is associated with early left ventricular diastolic dysfunction in patients with type 2 diabeteS
    Walaa Sheba, Eman Morsy, Salah Altahan, Mona Ayaad, Sameh A. Lashen
    Alexandria Journal of Medicine.2022; 58(1): 117.     CrossRef
  • The association between changes in hepatic steatosis and hepatic fibrosis with cardiovascular outcomes and mortality in patients with New-Onset type 2 Diabetes: A nationwide cohort study
    Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
    Diabetes Research and Clinical Practice.2022; 194: 110191.     CrossRef
  • Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (Diabetes Metab J 2022;46:630-9)
    Ji Hye Huh
    Diabetes & Metabolism Journal.2022; 46(6): 953.     CrossRef
  • The association of fatty liver index and BARD score with all-cause and cause-specific mortality in patients with type 2 diabetes mellitus: a nationwide population-based study
    Goh Eun Chung, Su-Min Jeong, Eun Ju Cho, Ji Won Yoon, Jeong-Ju Yoo, Yuri Cho, Kyu-na Lee, Dong Wook Shin, Yoon Jun Kim, Jung-Hwan Yoon, Kyungdo Han, Su Jong Yu
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Non-Albumin Proteinuria (NAP) as a Complementary Marker for Diabetic Kidney Disease (DKD)
    Jaehyun Bae, Young Jun Won, Byung-Wan Lee
    Life.2021; 11(3): 224.     CrossRef
  • Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
    Sook Jung Lee, Byung-Wan Lee
    The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
  • Non-alcoholic fatty liver disease
    Elizabeth E Powell, Vincent Wai-Sun Wong, Mary Rinella
    The Lancet.2021; 397(10290): 2212.     CrossRef
  • Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
    In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
    Scientific Reports.2021;[Epub]     CrossRef
  • Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
    Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
  • Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
    Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
    Journal of the Endocrine Society.2021;[Epub]     CrossRef
  • Reduced Rank Regression-Derived Dietary Patterns Related to the Fatty Liver Index and Associations with Type 2 Diabetes Mellitus among Ghanaian Populations under Transition: The RODAM Study
    Tracy Bonsu Osei, Anne-Marieke van Dijk, Sjoerd Dingerink, Felix Patience Chilunga, Erik Beune, Karlijn Anna Catharina Meeks, Silver Bahendeka, Matthias Bernd Schulze, Charles Agyemang, Mary Nicolaou, Adriaan Georgius Holleboom, Ina Danquah
    Nutrients.2021; 13(11): 3679.     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Liver fibrosis indices are related to diabetic peripheral neuropathy in individuals with type 2 diabetes
    Kyuho Kim, Tae Jung Oh, Hyen Chung Cho, Yun Kyung Lee, Chang Ho Ahn, Bo Kyung Koo, Jae Hoon Moon, Sung Hee Choi, Hak Chul Jang
    Scientific Reports.2021;[Epub]     CrossRef
  • Evaluation of Grapefruit Juice in terms of Interleukin 18 Gene Expression in Rats with Fatty Liver and Healthy Rats
    Simin Bahmanpoor, Noosha Zia-Jahromi
    journal of ilam university of medical sciences.2021; 29(4): 74.     CrossRef
Corrigenda: Table Correction. Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Yong-ho Lee, Yongin Cho, Byung-Wan Lee, Cheol-Young Park, Dae Ho Lee, Bong-Soo Cha, Eun-Jung Rhee
Diabetes Metab J. 2019;43(5):731-731.   Published online October 24, 2019
DOI: https://doi.org/10.4093/dmj.2019.0188
Corrects: Diabetes Metab J 2019;43(1):31
  • 3,298 View
  • 37 Download
PDFPubReader   
Clinical Diabetes & Therapeutics
Nonalcoholic Fatty Liver Disease and Diabetes: Part II: Treatment
Kyung-Soo Kim, Byung-Wan Lee, Yong Jin Kim, Dae Ho Lee, Bong-Soo Cha, Cheol-Young Park
Diabetes Metab J. 2019;43(2):127-143.   Published online April 15, 2019
DOI: https://doi.org/10.4093/dmj.2019.0034
  • 7,572 View
  • 138 Download
  • 25 Web of Science
  • 35 Crossref
AbstractAbstract PDFPubReader   

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders that are often comorbid conditions. Among many proposed treatments, weight reduction is the only approved option for NAFLD to date. However, it is not easy to maintain weight loss by lifestyle modification alone; pharmacological treatments are helpful in this regard. Although many drugs have been investigated, pioglitazone could be a first-line therapy in patients with NAFLD and diabetes. Many more drugs are currently being developed and investigated, and it is likely that combination strategies will be used for future treatment of NAFLD and diabetes. Attention should be paid to the management of NAFLD and diabetes and efforts should be made to intervene early and individualize treatment of NAFLD in patients with diabetes.

Citations

Citations to this article as recorded by  
  • Association of non-alcoholic fatty liver disease with cardiovascular disease and all cause death in patients with type 2 diabetes mellitus: nationwide population based study
    Kyung-Soo Kim, Sangmo Hong, Kyungdo Han, Cheol-Young Park
    BMJ.2024; : e076388.     CrossRef
  • Research Progress of Traditional Chinese Medicine and Western Medicine on Non-Alcoholic Fatty Liver Disease
    强江 郭
    Advances in Clinical Medicine.2024; 14(03): 561.     CrossRef
  • Liver and cardiovascular disease outcomes in metabolic syndrome and diabetic populations: Bi-directional opportunities to multiply preventive strategies
    Alhussain Yasin, Madison Nguyen, Angad Sidhu, Priyanka Majety, Jared Spitz, Amon Asgharpour, Mohammad S. Siddiqui, Laurence S. Sperling, Arshed A. Quyyumi, Anurag Mehta
    Diabetes Research and Clinical Practice.2024; : 111650.     CrossRef
  • Effect of aerobic training with silymarin consumption on glycemic indices and liver enzymes in men with type 2 diabetes
    Keyvan Ghalandari, Mojtaba Shabani, Ali Khajehlandi, Amin Mohammadi
    Archives of Physiology and Biochemistry.2023; 129(1): 76.     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Comparative antihypertensive efficacy of combinations of azilsartan medoxomil or olmesartan medoxomil with amlodipine in patients with arterial hypertension, type 2 diabetes mellitus and non-alcoholic fatty liver disease
    I. А. Lukonin, V. V. Skibitsky, A. V. Fendrikova, A. V. Skibitsky, I. A. Antipov
    South Russian Journal of Therapeutic Practice.2023; 4(1): 68.     CrossRef
  • An Ethyl Acetate Extract of Eryngium carlinae Inflorescences Attenuates Oxidative Stress and Inflammation in the Liver of Streptozotocin-Induced Diabetic Rats
    Cristian M. Trejo-Hurtado, Cinthia I. Landa-Moreno, Jenaro Lemus-de la Cruz, Donovan J. Peña-Montes, Rocío Montoya-Pérez, Rafael Salgado-Garciglia, Salvador Manzo-Avalos, Christian Cortés-Rojo, Juan Luis Monribot-Villanueva, José Antonio Guerrero-Analco,
    Antioxidants.2023; 12(6): 1235.     CrossRef
  • Pharmacogenetics of glucagon-like peptide-1 agonists in the treatment of type 2 diabetes mellitus
    Iu.G. Samoilova, A.E. Stankova, M.V. Matveeva, O.E. Vaizova, D.V. Podchinenova, D.A. Kudlay, T.A. Filippova, I.R. Grishkevich
    Profilakticheskaya meditsina.2023; 26(12): 95.     CrossRef
  • Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
    Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
    Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
  • Triglyceride and glucose index is a simple and easy‐to‐calculate marker associated with nonalcoholic fatty liver disease
    Kyung‐Soo Kim, Sangmo Hong, Hong‐Yup Ahn, Cheol‐Young Park
    Obesity.2022; 30(6): 1279.     CrossRef
  • Evaluating Triglyceride and Glucose Index as a Simple and Easy-to-Calculate Marker for All-Cause and Cardiovascular Mortality
    Kyung-Soo Kim, Sangmo Hong, You-Cheol Hwang, Hong-Yup Ahn, Cheol-Young Park
    Journal of General Internal Medicine.2022; 37(16): 4153.     CrossRef
  • Pharmacological Treatment of Nonalcoholic Fatty Liver Disease: Antidiabetic Agents
    Kyung-Soo Kim
    The Journal of Korean Diabetes.2022; 23(2): 83.     CrossRef
  • Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
    Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Intestinal microbiota in the treatment of metabolically associated fatty liver disease
    Ji-Shuai Wang, Jin-Chun Liu
    World Journal of Clinical Cases.2022; 10(31): 11240.     CrossRef
  • Efficiency of combined antihypertensive pharmacotherapy in patients with arterial hypertension, combined with type 2 diabetes mellitus and non-alcoholic fatty liver disease
    I. A. Lukonin, V. V. Skibitsky, A. V. Fendrikova, I. I. Pavlyuchenko, K. Yu. Lazarev, F. A. Kovalenko
    Systemic Hypertension.2022; 19(1): 31.     CrossRef
  • Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
    Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
    Nutrients.2022; 14(23): 4994.     CrossRef
  • Pluchea indica Leaf Extract Alleviates Dyslipidemia and Hepatic Steatosis by Modifying the Expression of Lipid Metabolism-Related Genes in Rats Fed a High Fat-High Fructose Diet
    Patcharin Singdam, Jarinyaporn Naowaboot, Laddawan Senggunprai, Kampeebhorn Boonloh, Patchareewan Pannangpetch
    Preventive Nutrition and Food Science.2022; 27(4): 384.     CrossRef
  • NAFLDin type 2 diabetes mellitus: Still many challenging questions
    Simona Cernea, Itamar Raz
    Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
  • Umbilical Cord-Mesenchymal Stem Cell-Conditioned Medium Improves Insulin Resistance in C2C12 Cell
    Kyung-Soo Kim, Yeon Kyung Choi, Mi Jin Kim, Jung Wook Hwang, Kyunghoon Min, Sang Youn Jung, Soo-Kyung Kim, Yong-Soo Choi, Yong-Wook Cho
    Diabetes & Metabolism Journal.2021; 45(2): 260.     CrossRef
  • Comparative Efficacy of Lobeglitazone Versus Pioglitazone on Albuminuria in Patients with Type 2 Diabetes Mellitus
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes Therapy.2021; 12(1): 171.     CrossRef
  • Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
    Sook Jung Lee, Byung-Wan Lee
    The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
  • Patient Management in Non-Alcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus
    A. E. Bagriy, A. D. Zubov, M. V. Khomenko, E. S. Mikhailichenko, E. A. Pylaeva, N. A. Khaustova, E. V. Bryukhovetskaya
    Russian Journal of Gastroenterology, Hepatology, Coloproctology.2021; 31(2): 14.     CrossRef
  • NAFLD and its link with diabetes: Why we should be worried
    Louise Cremonesini, Emma Harkin
    Independent Nurse.2021; 2021(8): 20.     CrossRef
  • Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
    Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
  • Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
    Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
    Rohit Loomba, Erin Morgan, Lynnetta Watts, Shuting Xia, Lisa A Hannan, Richard S Geary, Brenda F Baker, Sanjay Bhanot
    The Lancet Gastroenterology & Hepatology.2020; 5(9): 829.     CrossRef
  • Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
    Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
    Medicine.2020; 99(33): e21038.     CrossRef
  • Metabolic liver disease in diabetes – From mechanisms to clinical trials
    Bedair Dewidar, Sabine Kahl, Kalliopi Pafili, Michael Roden
    Metabolism.2020; 111: 154299.     CrossRef
  • Managing NAFLD in Type 2 Diabetes: The Effect of Lifestyle Interventions, a Narrative Review
    Siôn A. Parry, Leanne Hodson
    Advances in Therapy.2020; 37(4): 1381.     CrossRef
  • Diabetes and Metabolism Journal in 2020: Good to Great
    In-Kyung Jeong
    Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
  • Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
    Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
    Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
  • Molecular mechanisms of hepatic insulin resistance in nonalcoholic fatty liver disease and potential treatment strategies
    Chang-hua Zhang, Bu-gao Zhou, Jun-qing Sheng, Yang Chen, Ying-qian Cao, Chen Chen
    Pharmacological Research.2020; 159: 104984.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • Effects of sodium–glucose cotransporter 2 inhibitors on non‐alcoholic fatty liver disease in patients with type 2 diabetes: A meta‐analysis of randomized controlled trials
    Baodi Xing, Yuhang Zhao, Bingzi Dong, Yue Zhou, Wenshan Lv, Wenjuan Zhao
    Journal of Diabetes Investigation.2020; 11(5): 1238.     CrossRef
  • Empaglifozin mitigates NAFLD in high-fat-fed mice by alleviating insulin resistance, lipogenesis and ER stress
    Tamiris Ingrid Petito-da-Silva, Vanessa Souza-Mello, Sandra Barbosa-da-Silva
    Molecular and Cellular Endocrinology.2019; 498: 110539.     CrossRef
Complications
Nonalcoholic Fatty Liver Disease in Diabetes. Part I: Epidemiology and Diagnosis
Yong-ho Lee, Yongin Cho, Byung-Wan Lee, Cheol-Young Park, Dae Ho Lee, Bong-Soo Cha, Eun-Jung Rhee
Diabetes Metab J. 2019;43(1):31-45.   Published online December 17, 2018
DOI: https://doi.org/10.4093/dmj.2019.0011
Correction in: Diabetes Metab J 2019;43(5):731
  • 8,058 View
  • 165 Download
  • 106 Web of Science
  • 100 Crossref
AbstractAbstract PDFPubReader   

Nonalcoholic fatty liver disease (NAFLD) and diabetes are common metabolic disorders whose prevalence rates are expected to rise worldwide, corresponding to aging and increasingly obese populations. Compared to the general population (around 25%), 50% to 70% of people with diabetes have NAFLD, and NAFLD severity (including fibrosis) tends to be worsened by the presence of diabetes. NAFLD is considered an emerging risk factor for type 2 diabetes mellitus and a contributor to the development of chronic diabetes-related complications. This reciprocal relationship demonstrates the importance of confirming suspected NAFLD in patients with diabetes. Due to the invasive nature of liver biopsy to assess NAFLD status, various alternative non-invasive modalities have been developed and validated. Here, we summarized the epidemiology of NAFLD in patients with diabetes and reviewed currently available imaging modalities and biomarker-based prediction models for their ability to detect liver steatosis and/or fibrosis.

Citations

Citations to this article as recorded by  
  • Mortality in metabolic dysfunction-associated steatotic liver disease: A nationwide population-based cohort study
    Eugene Han, Byung-Wan Lee, Eun Seok Kang, Bong-Soo Cha, Sang Hoon Ahn, Yong-ho Lee, Seung Up Kim
    Metabolism.2024; 152: 155789.     CrossRef
  • Intact ketogenesis predicted reduced risk of moderate-severe metabolic-associated fatty liver disease assessed by liver transient elastography in newly diagnosed type 2 diabetes
    Sejeong Lee, Jaehyun Bae, Seung Up Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Frontiers in Endocrinology.2024;[Epub]     CrossRef
  • ZJU Index as a Predictive Tool for Diabetes Incidence: Insights from a Population-Based Cohort Study
    Chenjiao Wu, Yi Hao Loh, Hangkai Huang, Chengfu Xu
    Diabetes, Metabolic Syndrome and Obesity.2024; Volume 17: 715.     CrossRef
  • Sigmoidal relationship between liver fat content and nonalcoholic fatty liver disease in Chinese adults
    Pingping Yu, Huachao Yang, Hu Li, Ying Mei, Yuanyuan Wu, Hongfeng Cheng, Huiru Su, Yueling Deng, Tao Jiang, Zhongxiang He, Peng Hu
    Postgraduate Medical Journal.2024;[Epub]     CrossRef
  • Safety and Efficacy of Efruxifermin in Combination With a GLP-1 Receptor Agonist in Patients With NASH/MASH and Type 2 Diabetes in a Randomized Phase 2 Study
    Stephen A. Harrison, Juan P. Frias, K. Jean Lucas, Gary Reiss, Guy Neff, Sureka Bollepalli, Yan Su, Doreen Chan, Erik J. Tillman, Ali Moulton, Brittany de Temple, Arian Zari, Reshma Shringarpure, Timothy Rolph, Andrew Cheng, Kitty Yale
    Clinical Gastroenterology and Hepatology.2024;[Epub]     CrossRef
  • Plasma Adiponectin and Its Correlation with Carotid Intima-Media Thickness in Obesity and in Type 2 Diabetes and Nonalcoholic Fatty Liver Disease
    Maha Hussein, Aasem Saif, Mona Amin, Osama Khalafallah, Ahmed Hussien, Samar Aboulsoud, Shrook Mousa, S. Razzaque Mohammed
    Journal of Nutrition and Metabolism.2023; 2023: 1.     CrossRef
  • Exposure to Bisphenol A, S, and F and its Association with Obesity and Diabetes Mellitus in General Adults of Korea: Korean National Environmental Health Survey (KoNEHS) 2015–2017
    Min Kyong Moon, Min Joo Kim, Inae Lee, Sunmi Kim, Sohyeon Choi, Jeongim Park, Yoon Hee Cho, Sooyeon Hong, Jiyoung Yoo, Hyunwoong Park, Gi Jeong Cheon, Young Joo Park, Kyungho Choi
    Exposure and Health.2023; 15(1): 53.     CrossRef
  • Liver fat content assessed by conventional B-mode ultrasound and metabolic profile in non-diabetic patients: Implications for clinical practice
    Rosanna Villani, Grazia Pia Magnati, Giulia Tuccari, Moris Sangineto, Antonino Davide Romano, Tommaso Cassano, Gaetano Serviddio
    Ultrasound.2023; 31(3): 177.     CrossRef
  • Association of cardiovascular health metrics with annual incidence of prediabetes or diabetes: Analysis of a nationwide real‐world database
    Akira Okada, Hidehiro Kaneko, Satoshi Matsuoka, Hidetaka Itoh, Yuta Suzuki, Katsuhito Fujiu, Nobuaki Michihata, Taisuke Jo, Norifumi Takeda, Hiroyuki Morita, Satoko Yamaguchi, Koichi Node, Toshimasa Yamauchi, Hideo Yasunaga, Issei Komuro
    Journal of Diabetes Investigation.2023; 14(3): 452.     CrossRef
  • Effects of Environmental Cadmium Exposure on the Liver in Korean Adults: Cross-Sectional and Longitudinal Studies
    Mi-Na Seo, Sang-Yong Eom, Ji-Ae Lim, Jung-Eum Lee, Byung-Sun Choi, Ho-Jang Kwon, Young-Seoub Hong, Heon Kim, Jung-Duck Park
    Archives of Environmental Contamination and Toxicology.2023; 84(2): 237.     CrossRef
  • Newer Glucose-Lowering Therapies in Older Adults with Type 2 Diabetes
    Anika Bilal, Richard E. Pratley
    Endocrinology and Metabolism Clinics of North America.2023; 52(2): 355.     CrossRef
  • CD24 Gene Expression as a Risk Factor for Non-Alcoholic Fatty Liver Disease
    Mona A. Amin, Halla M. Ragab, Nabila Abd El Maksoud, Wafaa Abd Elaziz
    Diagnostics.2023; 13(5): 984.     CrossRef
  • Metabolic Dysfunction-Associated Fatty Liver Disease and Mortality: A Population-Based Cohort Study
    Kyung-Soo Kim, Sangmo Hong, Hong-Yup Ahn, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(2): 220.     CrossRef
  • Non-Alcoholic Fatty Liver Disease with Sarcopenia and Carotid Plaque Progression Risk in Patients with Type 2 Diabetes Mellitus
    Yongin Cho, Hye-Sun Park, Byung Wook Huh, Yong-ho Lee, Seong Ha Seo, Da Hea Seo, Seong Hee Ahn, Seongbin Hong, So Hun Kim
    Diabetes & Metabolism Journal.2023; 47(2): 232.     CrossRef
  • Nonalcoholic fatty liver disease and type 2 diabetes: an observational and Mendelian randomization study
    Yuetian Yu, Yuefeng Yu, Yuying Wang, Yi Chen, Ningjian Wang, Bin Wang, Yingli Lu
    Frontiers in Endocrinology.2023;[Epub]     CrossRef
  • β-sitosterol attenuates high- fat diet-induced hepatic steatosis in rats by modulating lipid metabolism, inflammation and ER stress pathway
    Omayma AR Abo-Zaid, Fatma SM Moawed, Effet Soliman Ismail, Mostafa A. Farrag
    BMC Pharmacology and Toxicology.2023;[Epub]     CrossRef
  • Fatty Liver & Diabetes Statistics in Korea: Nationwide Data 2009 to 2017
    Eugene Han, Kyung-Do Han, Yong-ho Lee, Kyung-Soo Kim, Sangmo Hong, Jung Hwan Park, Cheol-Young Park
    Diabetes & Metabolism Journal.2023; 47(3): 347.     CrossRef
  • Increased expression of sodium-glucose cotransporter 2 and O-GlcNAcylation in hepatocytes drives non-alcoholic steatohepatitis
    Hye Jin Chun, Eun Ran Kim, Minyoung Lee, Da Hyun Choi, Soo Hyun Kim, Eugene Shin, Jin-Hong Kim, Jin Won Cho, Dai Hoon Han, Bong-Soo Cha, Yong-ho Lee
    Metabolism.2023; 145: 155612.     CrossRef
  • Role of vascular endothelial growth factor B in nonalcoholic fatty liver disease and its potential value
    Yu-Qi Li, Lei Xin, Yu-Chi Zhao, Shang-Qi Li, Ya-Nuo Li
    World Journal of Hepatology.2023; 15(6): 786.     CrossRef
  • Increased risk of incident diabetes in patients with MAFLD not meeting the criteria for NAFLD
    So Hee Park, Jiyun Park, So Yoon Kwon, You-Bin Lee, Gyuri Kim, Kyu Yeon Hur, Janghyun Koh, Jae Hwan Jee, Jae Hyeon Kim, Mira Kang, Sang-Man Jin
    Scientific Reports.2023;[Epub]     CrossRef
  • Significance of Diabetic Kidney Disease Biomarkers in Predicting Metabolic-Associated Fatty Liver Disease
    Jaehyun Bae, Byung-Wan Lee
    Biomedicines.2023; 11(7): 1928.     CrossRef
  • An Evidence-Based Review of Diabetes Care: History, Types, Relationship to Cancer and Heart Disease, Co-Morbid Factors, and Preventive Measures
    Umesh Chandra Gupta, Subhas Chandra Gupta, Shayle Sugandh Gupta
    Current Nutrition & Food Science.2023; 19(4): 399.     CrossRef
  • Associations of serum aminotransferase and the risk of all-cause and cause-specific mortality in Chinese type 2 diabetes: a community-based cohort study
    Jian Su, Haoyu Guan, Xikang Fan, Hao Yu, Yu Qin, Jie Yang, Zheng Zhu, Chong Shen, Enchun Pan, Yan Lu, Jin-Yi Zhou, Ming Wu
    BMJ Open.2023; 13(7): e068160.     CrossRef
  • Retinoic acid signaling in fatty liver disease
    Fathima N. Cassim Bawa, Yanqiao Zhang
    Liver Research.2023; 7(3): 189.     CrossRef
  • Pharmaceutical Strategies to Improve Druggability of Potential Drug Candidates in Nonalcoholic Fatty Liver Disease Therapy
    Reeju Amatya, Donghee Lee, Kyoung Ah Min, Meong Cheol Shin
    Pharmaceutics.2023; 15(7): 1963.     CrossRef
  • Prevalence of Non-Alcoholic Fatty Liver Disease and Its Risk Factors in Korean Population
    Sang Gyeong Lee, Songchan Oh, Moon Seong Kim, Jooyeon Kim, Eunjin Jung, Young Jun Kim, Jiyoun Hong
    Food Supplements and Biomaterials for Health.2023;[Epub]     CrossRef
  • Low‑dose ionizing radiation attenuates high glucose‑induced hepatic apoptosis and immune factor release via modulation of a miR‑155‑SOCS1 axis
    Hongqiong Fan, Shanshan Liu, Benzheng Jiao, Xinyue Liang
    Molecular Medicine Reports.2023;[Epub]     CrossRef
  • CT-based measurement of visceral adipose tissue volume as a reliable tool for assessing metabolic risk factors in prediabetes across subtypes
    Jihyun Kim, Keunyoung Kim
    Scientific Reports.2023;[Epub]     CrossRef
  • The Role of the Fatty Liver Index (FLI) in the Management of Non-Alcoholic Fatty Liver Disease: A Systematic Review
    Teodora Biciusca, Sorina Ionelia Stan, Mara Amalia Balteanu, Ramona Cioboata, Alice Elena Ghenea, Suzana Danoiu, Ana-Maria Bumbea, Viorel Biciusca
    Diagnostics.2023; 13(21): 3316.     CrossRef
  • Circ_0004535/miR-1827/CASP8 network involved in type 2 diabetes mellitus with nonalcoholic fatty liver disease
    Min Li, Ai Zeng, Xinle Tang, Hui Xu, Wei Xiong, Yanying Guo
    Scientific Reports.2023;[Epub]     CrossRef
  • Prevalence of High and Moderate Risk of Liver Fibrosis Among Patients With Diabetes at a Noncommunicable Diseases (NCD) Clinic in a Primary Healthcare Center in Northern India
    Anubhav Mondal, Aninda Debnath, Ghurumourthy Dhandapani, Abhishek Sharma, Shveta Lukhmana, Geeta Yadav
    Cureus.2023;[Epub]     CrossRef
  • Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients
    Mazhar Hussain, Muhammad Zafar Majeed Babar, Saba Tariq, Muhammad Irfan Ahmad, Lubna Akhtar
    International Journal of Diabetes in Developing Countries.2022; 42(2): 290.     CrossRef
  • Lead, mercury, and cadmium exposures are associated with obesity but not with diabetes mellitus: Korean National Environmental Health Survey (KoNEHS) 2015–2017
    Min Kyong Moon, Inae Lee, Aram Lee, Hyunwoong Park, Min Joo Kim, Sunmi Kim, Yoon Hee Cho, Sooyeon Hong, Jiyoung Yoo, Gi Jeong Cheon, Kyungho Choi, Young Joo Park, Jeongim Park
    Environmental Research.2022; 204: 111888.     CrossRef
  • Association of Prenatal Famine Exposure With Inflammatory Markers and Its Impact on Adulthood Liver Function Across Consecutive Generations
    Shiwei Yan, Jingqi Ruan, Yu Wang, Jiaxu Xu, Changhao Sun, Yucun Niu
    Frontiers in Nutrition.2022;[Epub]     CrossRef
  • Serum Metabolomics in Patients with Coexisting NAFLD and T2DM Using Liquid Chromatography-Mass Spectrometry
    Cheng Hu, Xiaoyu Zhuang, Jiaqi Zhang, Tao Wang, Shengnan Du, Jinping Wang, Xuelian Peng, Qin Cao, Mingcai Zhang, Yuanye Jiang
    Laboratory Medicine.2022; 53(4): 360.     CrossRef
  • Genistein—Opportunities Related to an Interesting Molecule of Natural Origin
    Ewa Garbiec, Judyta Cielecka-Piontek, Magdalena Kowalówka, Magdalena Hołubiec, Przemysław Zalewski
    Molecules.2022; 27(3): 815.     CrossRef
  • Renal Tubular Damage Marker, Urinary N-acetyl-β-D-Glucosaminidase, as a Predictive Marker of Hepatic Fibrosis in Type 2 Diabetes Mellitus
    Hae Kyung Kim, Minyoung Lee, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-Wan Lee
    Diabetes & Metabolism Journal.2022; 46(1): 104.     CrossRef
  • Long-term effects of the changes in hepatic steatosis status on the risk of incident type 2 diabetes mellitus: A 15-year community-based prospective cohort study
    Seung Min Chung, Min Kyu Kang, Jinho Jung, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee, Rohit Loomba, Jung Gil Park, Jun Sung Moon
    Diabetes Research and Clinical Practice.2022; 184: 109208.     CrossRef
  • Prevalence and Risk Factors of Advanced Liver Fibrosis in a Population‐Based Study in Germany
    Yvonne Huber, Andreas Schulz, Irene Schmidtmann, Manfred Beutel, Norbert Pfeiffer, Thomas Münzel, Peter R. Galle, Philipp S. Wild, Karl J. Lackner, Jörn M. Schattenberg
    Hepatology Communications.2022; 6(6): 1457.     CrossRef
  • Non-alcoholic fatty liver disease: Epidemiology, pathophysiology and an update on the therapeutic approaches
    RehabF Abdel-Rahman
    Asian Pacific Journal of Tropical Biomedicine.2022; 12(3): 99.     CrossRef
  • State-of-the-Art Overview of the Pharmacological Treatment of Non-Alcoholic Steatohepatitis
    Yongin Cho, Yong-ho Lee
    Endocrinology and Metabolism.2022; 37(1): 38.     CrossRef
  • Obesity is an important determinant of severity in newly defined metabolic dysfunction-associated fatty liver disease
    Ji Hye Huh, Kwang Joon Kim, Seung Up Kim, Bong-Soo Cha, Byung-Wan Lee
    Hepatobiliary & Pancreatic Diseases International.2022; 21(3): 241.     CrossRef
  • The associations of hepatic steatosis and fibrosis using fatty liver index and BARD score with cardiovascular outcomes and mortality in patients with new-onset type 2 diabetes: a nationwide cohort study
    Jiyun Park, Gyuri Kim, Bong-Sung Kim, Kyung-Do Han, So Yoon Kwon, So Hee Park, You-Bin Lee, Sang-Man Jin, Jae Hyeon Kim
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Sociodemographic and genetic determinants of nonalcoholic fatty liver disease in type 2 diabetes mellitus patients
    Muhammad Adnan, Abdul Wajid, Wasif Noor, Andleeb Batool, Muhammad Aasim, Kamran Abbas, Quratul Ain
    Journal of Genetic Engineering and Biotechnology.2022; 20(1): 68.     CrossRef
  • Concordance between indirect fibrosis and steatosis indices and their predictors in subjects with overweight/obesity
    Gaggini Melania, Vigna Luisella, Di Piazza Salvina, Gori Francesca, Tirelli Amedea Silvia, Bamonti Fabrizia, Maltinti Maristella, Napolitano Filomena, Chatzianagnostou Kyriazoula, Cristina Vassalle
    Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity.2022; 27(7): 2617.     CrossRef
  • Stéatopathie métabolique hépatique évaluée par le FibroScan® avec contrôle des paramètres d’atténuation (CAP) chez la personne diabétique de type 2 en Côte d’Ivoire
    Jacko Abodo, Dimitri Kouamé, Jocelyne Danho, Moumouni Léilatou, Pierre Koffi-Dago, Adelaïde Hué, Assita Yao, Franck Kouassi, Anselme N’Guessan, Fulgence Bathaix
    Médecine des Maladies Métaboliques.2022; 16(6): 550.     CrossRef
  • Non-invasive diagnosis and staging of non-alcoholic fatty liver disease
    Stergios Kechagias, Mattias Ekstedt, Christian Simonsson, Patrik Nasr
    Hormones.2022; 21(3): 349.     CrossRef
  • Association between organochlorine pesticides and nonalcoholic fatty liver disease in the National Health and Nutrition Examination Survey 2003–2004
    Hyunji Sang, Kyu-Na Lee, Chang Hee Jung, Kyungdo Han, Eun Hee Koh
    Scientific Reports.2022;[Epub]     CrossRef
  • Increased Risk of NAFLD in Adults with Glomerular Hyperfiltration: An 8-Year Cohort Study Based on 147,162 Koreans
    Dae-Jeong Koo, Mi Yeon Lee, Inha Jung, Sun Joon Moon, Hyemi Kwon, Eun-Jung Rhee, Cheol-Young Park, Won-Young Lee, Ki Won Oh, Se Eun Park
    Journal of Personalized Medicine.2022; 12(7): 1142.     CrossRef
  • Advanced Liver Fibrosis Is Associated with Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Da Hea Seo, Young Ju Suh, Yongin Cho, Seong Hee Ahn, Seongha Seo, Seongbin Hong, Yong-ho Lee, Young Ju Choi, Eunjig Lee, So Hun Kim
    Diabetes & Metabolism Journal.2022; 46(4): 630.     CrossRef
  • New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis
    Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
    Life.2022; 12(8): 1189.     CrossRef
  • Efficacy and mechanism of Jiedu Tongluo Tiaogan Formula in treating type 2 diabetes mellitus combined with non-alcoholic fatty liver disease: Study protocol for a parallel-armed, randomized controlled trial
    Jinghan Xu, Chunli Piao, Yue Qu, Tianjiao Liu, Yuting Peng, Qi Li, Xiaohua Zhao, Pei Li, Xuemin Wu, Yawen Fan, Binqin Chen, Jie Yang
    Frontiers in Pharmacology.2022;[Epub]     CrossRef
  • Ultrasound-Based Hepatic Elastography in Non-Alcoholic Fatty Liver Disease: Focus on Patients with Type 2 Diabetes
    Georgiana-Diana Cazac, Cristina-Mihaela Lăcătușu, Cătălina Mihai, Elena-Daniela Grigorescu, Alina Onofriescu, Bogdan-Mircea Mihai
    Biomedicines.2022; 10(10): 2375.     CrossRef
  • Diosgenin Ameliorated Type II Diabetes-Associated Nonalcoholic Fatty Liver Disease through Inhibiting De Novo Lipogenesis and Improving Fatty Acid Oxidation and Mitochondrial Function in Rats
    Yujie Zhong, Zhiman Li, Ruyi Jin, Yanpeng Yao, Silan He, Min Lei, Xin Wang, Chao Shi, Li Gao, Xiaoli Peng
    Nutrients.2022; 14(23): 4994.     CrossRef
  • The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study
    Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, Sang-Man Jin, Jae Hyeon Kim
    Cardiovascular Diabetology.2022;[Epub]     CrossRef
  • Recent advances and potentiality of postbiotics in the food industry: Composition, inactivation methods, current applications in metabolic syndrome, and future trends
    Yujie Zhong, Tao Wang, Ruilin Luo, Jiayu Liu, Ruyi Jin, Xiaoli Peng
    Critical Reviews in Food Science and Nutrition.2022; : 1.     CrossRef
  • Association of nonalcoholic fatty liver disease with coronary artery disease in type 2 diabetes mellitus: A cross-sectional study from a tertiary care medical college hospital
    Neelakandan Ramya, Golepu Karthikeya, SethuPrabhu Shankar
    Acta Medica International.2022; 9(1): 31.     CrossRef
  • NAFLDin type 2 diabetes mellitus: Still many challenging questions
    Simona Cernea, Itamar Raz
    Diabetes/Metabolism Research and Reviews.2021;[Epub]     CrossRef
  • The protective effect of shrimp cooked in different methods on high-cholesterol- induced fatty liver in rats
    Nora A. AlFaris, Ghedeir M. Alshammari, Jozaa Z. AlTamimi, Lujain A. AlMousa, Nora M. AlKehayez, Dalal H. Aljabryn, Reham I. Alagal, Mohammed A. Yahya
    Saudi Journal of Biological Sciences.2021; 28(1): 170.     CrossRef
  • Evolution of liver fibrosis and steatosis markers in patients with type 2 diabetes after metformin treatment for 2 years
    Hye Won Lee, Jae Seung Lee, Beom Kyung Kim, Jun Yong Park, Do Young Kim, Sang Hoon Ahn, Seung Up Kim
    Journal of Diabetes and its Complications.2021; 35(1): 107747.     CrossRef
  • Prognostic value of non-alcoholic fatty liver disease for predicting cardiovascular events in patients with diabetes mellitus with suspected coronary artery disease: a prospective cohort study
    Keishi Ichikawa, Toru Miyoshi, Kazuhiro Osawa, Takashi Miki, Hironobu Toda, Kentaro Ejiri, Masatoki Yoshida, Yusuke Nanba, Masashi Yoshida, Kazufumi Nakamura, Hiroshi Morita, Hiroshi Ito
    Cardiovascular Diabetology.2021;[Epub]     CrossRef
  • Implications of Abdominal Adipose Tissue Distribution on Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: A Chinese General Population Study
    Chileka Chiyanika, Vincent Wai-Sun Wong, Grace Lai-Hung Wong, Henry Lik-Yuen Chan, Steve C. N. Hui, David K. W. Yeung, Winnie C. W. Chu
    Clinical and Translational Gastroenterology.2021; 12(2): e00300.     CrossRef
  • Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: Diagnosis and Treatment
    Sook Jung Lee, Byung-Wan Lee
    The Journal of Korean Diabetes.2021; 22(1): 38.     CrossRef
  • Pioglitazone for NAFLD Patients With Prediabetes or Type 2 Diabetes Mellitus: A Meta-Analysis
    Jingxuan Lian, Jianfang Fu
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Allopurinol ameliorates high fructose diet induced hepatic steatosis in diabetic rats through modulation of lipid metabolism, inflammation, and ER stress pathway
    In-Jin Cho, Da-Hee Oh, Jin Yoo, You-Cheol Hwang, Kyu Jeung Ahn, Ho-Yeon Chung, Soung Won Jeong, Ju-Young Moon, Sang-Ho Lee, Sung-Jig Lim, In-Kyung Jeong
    Scientific Reports.2021;[Epub]     CrossRef
  • Diabetic Kidney Disease, Cardiovascular Disease and Non-Alcoholic Fatty Liver Disease: A New Triumvirate?
    Carolina M. Perdomo, Nuria Garcia-Fernandez, Javier Escalada
    Journal of Clinical Medicine.2021; 10(9): 2040.     CrossRef
  • Fenofibrate, a PPARα agonist, reduces hepatic fat accumulation through the upregulation of TFEB-mediated lipophagy
    Jin Yoo, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You-Cheol Hwang
    Metabolism.2021; 120: 154798.     CrossRef
  • Association Between Thyroid Hormone Levels and Advanced Liver Fibrosis in Patients with Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease
    Jing Du, Sanbao Chai, Xin Zhao, Jianbin Sun, Xiaomei Zhang, Lili Huo
    Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy.2021; Volume 14: 2399.     CrossRef
  • Association between toothbrushing and non-alcoholic fatty liver disease
    Ji-Youn Kim, Yong-Moon Park, Gyu-Na Lee, Hyun Chul Song, Yu-Bae Ahn, Kyungdo Han, Seung-Hyun Ko, Houkai Li
    PLOS ONE.2021; 16(5): e0243686.     CrossRef
  • Non‐alcoholic fatty liver disease and sarcopenia additively increase mortality: a Korean nationwide survey
    Joon Ho Moon, Bo Kyung Koo, Won Kim
    Journal of Cachexia, Sarcopenia and Muscle.2021; 12(4): 964.     CrossRef
  • Sodium-Glucose Cotransporter-2 Inhibitors Ameliorate Liver Enzyme Abnormalities in Korean Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Won Euh, Soo Lim, Jin-Wook Kim
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Modulation and bioinformatics screening of hepatic mRNA-lncRNAs (HML) network associated with insulin resistance in prediabetic and exercised mice
    Fatemeh Kazeminasab, Sayed Mohammad Marandi, Maryam Baharlooie, Mohammad Hossein Nasr-Esfahani, Kamran Ghaedi
    Nutrition & Metabolism.2021;[Epub]     CrossRef
  • Liver Fibrosis Indices for the Prediction of Mortality in Korean Subjects: A 16-Year Prospective Cohort Study
    Tae Jung Oh, Kyuho Kim, Jae Hoon Moon, Sung Hee Choi, Nam H Cho, Hak Chul Jang
    Journal of the Endocrine Society.2021;[Epub]     CrossRef
  • Non-Laboratory-Based Simple Screening Model for Nonalcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Developed Using Multi-Center Cohorts
    Jiwon Kim, Minyoung Lee, Soo Yeon Kim, Ji-Hye Kim, Ji Sun Nam, Sung Wan Chun, Se Eun Park, Kwang Joon Kim, Yong-ho Lee, Joo Young Nam, Eun Seok Kang
    Endocrinology and Metabolism.2021; 36(4): 823.     CrossRef
  • The association of hepatic steatosis and fibrosis with heart failure and mortality
    Jiyun Park, Gyuri Kim, Hasung Kim, Jungkuk Lee, You-Bin Lee, Sang-Man Jin, Kyu Yeon Hur, Jae Hyeon Kim
    Cardiovascular Diabetology.2021;[Epub]     CrossRef
  • Magnetic Resonance-Based Assessments Better Capture Pathophysiologic Profiles and Progression in Nonalcoholic Fatty Liver Disease
    Seung Joon Choi, Seong Min Kim, Yun Soo Kim, Oh Sang Kwon, Seung Kak Shin, Kyoung Kon Kim, Kiyoung Lee, Ie Byung Park, Cheol Soo Choi, Dong Hae Chung, Jaehun Jung, MunYoung Paek, Dae Ho Lee
    Diabetes & Metabolism Journal.2021; 45(5): 739.     CrossRef
  • Albuminuria Is Associated with Steatosis Burden in Patients with Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
    Eugene Han, Mi Kyung Kim, Byoung Kuk Jang, Hye Soon Kim
    Diabetes & Metabolism Journal.2021; 45(5): 698.     CrossRef
  • The potential pathophysiological role of altered lipid metabolism and electronegative low-density lipoprotein (LDL) in non-alcoholic fatty liver disease and cardiovascular diseases
    Hüseyin Vural, Ferah Armutcu, Omer Akyol, Ralf Weiskirchen
    Clinica Chimica Acta.2021; 523: 374.     CrossRef
  • Increased Visit-to-Visit Liver Enzyme Variability Is Associated with Incident Diabetes: A Community-Based 12-Year Prospective Cohort Study
    Kyuhoon Bang, Ji Eun Jun, In-Kyung Jeong, Kyu Jeung Ahn, Ho Yeon Chung, You-Cheol Hwang
    Diabetes & Metabolism Journal.2021; 45(6): 890.     CrossRef
  • Efficacy and Safety of GLP-1 Receptor Agonists in Patients With Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Yuan Zhu, Jiao Xu, Dong Zhang, Xingyu Mu, Yi Shi, Shangtao Chen, Zengxiang Wu, Shuangqing Li
    Frontiers in Endocrinology.2021;[Epub]     CrossRef
  • Triglyceride Glucose-Waist Circumference Is Superior to the Homeostasis Model Assessment of Insulin Resistance in Identifying Nonalcoholic Fatty Liver Disease in Healthy Subjects
    Hwi Seung Kim, Yun Kyung Cho, Eun Hee Kim, Min Jung Lee, Chang Hee Jung, Joong-Yeol Park, Hong-Kyu Kim, Woo Je Lee
    Journal of Clinical Medicine.2021; 11(1): 41.     CrossRef
  • The association between nonalcoholic fatty liver disease and esophageal, stomach, or colorectal cancer: National population-based cohort study
    Jung-Min Lee, Yong-Moon Park, Jae-Seung Yun, Yu-Bae Ahn, Kang-Moon Lee, Dae Bum Kim, Ji Min Lee, Kyungdo Han, Seung-Hyun Ko, Ming-Lung Yu
    PLOS ONE.2020; 15(1): e0226351.     CrossRef
  • Non-alcoholic steatohepatitis and progression of carotid atherosclerosis in patients with type 2 diabetes: a Korean cohort study
    Hyeok-Hee Lee, Yongin Cho, Young Ju Choi, Byung Wook Huh, Byung-Wan Lee, Eun Seok Kang, Seok Won Park, Bong-Soo Cha, Eun Jig Lee, Yong-ho Lee, Kap Bum Huh
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Visceral-to-Subcutaneous Abdominal Fat Ratio Is Associated with Nonalcoholic Fatty Liver Disease and Liver Fibrosis
    Chan-Hee Jung, Eun-Jung Rhee, Hyemi Kwon, Yoosoo Chang, Seungho Ryu, Won-Young Lee
    Endocrinology and Metabolism.2020; 35(1): 165.     CrossRef
  • Fatty liver index and development of cardiovascular disease in Koreans without pre-existing myocardial infarction and ischemic stroke: a large population-based study
    Jun Hyung Kim, Jin Sil Moon, Seok Joon Byun, Jun Hyeok Lee, Dae Ryong Kang, Ki Chul Sung, Jang Young Kim, Ji Hye Huh
    Cardiovascular Diabetology.2020;[Epub]     CrossRef
  • Non-invasive diagnosis of nonalcoholic fatty liver disease: impact of age and other risk factors
    Muharrem Bayrak
    The Aging Male.2020; 23(5): 1275.     CrossRef
  • Establishment of a Risk Prediction Model for Non-alcoholic Fatty Liver Disease in Type 2 Diabetes
    Yali Zhang, Rong Shi, Liang Yu, Liping Ji, Min Li, Fan Hu
    Diabetes Therapy.2020; 11(9): 2057.     CrossRef
  • Noninvasive Evaluation of Nonalcoholic Fatty Liver Disease
    Dae Ho Lee
    Endocrinology and Metabolism.2020; 35(2): 243.     CrossRef
  • Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association
    Byung-Wan Lee, Yong-ho Lee, Cheol-Young Park, Eun-Jung Rhee, Won-Young Lee, Nan-Hee Kim, Kyung Mook Choi, Keun-Gyu Park, Yeon-Kyung Choi, Bong-Soo Cha, Dae Ho Lee
    Diabetes & Metabolism Journal.2020; 44(3): 382.     CrossRef
  • Sarcopenia is associated with non-alcoholic fatty liver disease in men with type 2 diabetes
    D.H. Seo, Y.-h. Lee, S.W. Park, Y.J. Choi, B.W. Huh, E. Lee, K.B. Huh, S.H. Kim, B.-S. Cha
    Diabetes & Metabolism.2020; 46(5): 362.     CrossRef
  • Pharmacological Strategies for Insulin Sensitivity in Obesity and Cancer: Thiazolidinediones and Metformin
    Luana A. Biondo, Alexandre A. S. Teixeira, Karen C. de O. S. Ferreira, Jose C. R. Neto
    Current Pharmaceutical Design.2020; 26(9): 932.     CrossRef
  • Diabetes and Metabolism Journal in 2020: Good to Great
    In-Kyung Jeong
    Diabetes & Metabolism Journal.2020; 44(1): 1.     CrossRef
  • Toll-like receptor 9, a possible blocker of non-alcoholic steatohepatitis?
    Soung Won Jeong
    Clinical and Molecular Hepatology.2020; 26(2): 185.     CrossRef
  • The sex-specific effects of blood lead, mercury, and cadmium levels on hepatic steatosis and fibrosis: Korean nationwide cross-sectional study
    Seung Min Chung, Jun Sung Moon, Ji Sung Yoon, Kyu Chang Won, Hyoung Woo Lee
    Journal of Trace Elements in Medicine and Biology.2020; 62: 126601.     CrossRef
  • Hepatic fibrosis is associated with total proteinuria in Korean patients with type 2 diabetes
    Eugene Han, Yongin Cho, Kyung-won Kim, Yong-ho Lee, Eun Seok Kang, Bong-Soo Cha, Byung-wan Lee
    Medicine.2020; 99(33): e21038.     CrossRef
  • Causal relationships between NAFLD, T2D and obesity have implications for disease subphenotyping
    Zhipeng Liu, Yang Zhang, Sarah Graham, Xiaokun Wang, Defeng Cai, Menghao Huang, Roger Pique-Regi, Xiaocheng Charlie Dong, Y. Eugene Chen, Cristen Willer, Wanqing Liu
    Journal of Hepatology.2020; 73(2): 263.     CrossRef
  • Prevalence of Nonalcoholic Fatty Liver Disease (NAFLD) in Patients With Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis
    Marieke de Vries, Jan Westerink, Karin H A H Kaasjager, Harold W de Valk
    The Journal of Clinical Endocrinology & Metabolism.2020; 105(12): 3842.     CrossRef
  • Beneficial effect of anti-diabetic drugs for nonalcoholic fatty liver disease
    Kyung-Soo Kim, Byung-Wan Lee
    Clinical and Molecular Hepatology.2020; 26(4): 430.     CrossRef
  • Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective
    Eun-Jung Rhee
    Endocrinology and Metabolism.2019; 34(3): 226.     CrossRef
  • Role of sodium-glucose co-transporter-2 inhibitors in the management of nonalcoholic fatty liver disease
    Anastasia Kontana, Konstantinos Tziomalos
    World Journal of Gastroenterology.2019; 25(28): 3664.     CrossRef
Letter: Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database (Diabetes Metab J 2015;39:247-52)
Dae Ho Lee
Diabetes Metab J. 2015;39(4):348-349.   Published online August 17, 2015
DOI: https://doi.org/10.4093/dmj.2015.39.4.348
  • 2,549 View
  • 23 Download
  • 2 Web of Science
  • 2 Crossref
PDFPubReader   

Citations

Citations to this article as recorded by  
  • Heart failure and diabetes: Clinical significance and epidemiology of this two‐way association
    Terri Jerkins, Janet B. McGill, David S. H. Bell
    Diabetes, Obesity and Metabolism.2023; 25(S3): 3.     CrossRef
  • Heart failure in the patient with diabetes: Epidemiology, aetiology, prognosis, therapy and the effect of glucose‐lowering medications
    David S. H. Bell, Edison Goncalves
    Diabetes, Obesity and Metabolism.2019; 21(6): 1277.     CrossRef
Lipoproteins and β-Cell Functions: From Basic to Clinical Data
Dae Ho Lee
Diabetes Metab J. 2014;38(4):274-277.   Published online August 20, 2014
DOI: https://doi.org/10.4093/dmj.2014.38.4.274
  • 2,654 View
  • 33 Download
  • 1 Web of Science
  • 2 Crossref
PDFPubReader   

Citations

Citations to this article as recorded by  
  • Association between lipids and apolipoproteins on type 2 diabetes risk; moderating effects of gender and polymorphisms; the ATTICA study
    Duane D. Mellor, Ekavi N. Georgousopoulou, Nathan M. D'Cunha, Nenad Naumovski, Christina Chrysohoou, Dimitrios Tousoulis, Christos Pitsavos, Demosthenes B. Panagiotakos
    Nutrition, Metabolism and Cardiovascular Diseases.2020; 30(5): 788.     CrossRef
  • Effects of 7-Hydroxy-2-(4-hydroxy-3-methoxyphenyl)-chromen-4 -one from Swietenia macrophylla King Seed on Oxidized LDL, HOMA Beta and Glucagon like Peptide 1 (GLP-1) Gene Expression in Type 2 Diabetic Rats
    Prasetyastuti ., Sunarti ., Ahmad Hamim Sadewa, Sri Mursiti, Mustofa .
    Asian Journal of Biochemistry.2017; 12(3): 85.     CrossRef
Clinical Characteristics of Type 2 Diabetes Patients according to Family History of Diabetes
Seung Uk Jeong, Dong Gu Kang, Dae Ho Lee, Kang Woo Lee, Dong-Mee Lim, Byung Joon Kim, Keun-Yong Park, Hyoun-Jung Chin, Gwanpyo Koh
Korean Diabetes J. 2010;34(4):222-228.   Published online August 31, 2010
DOI: https://doi.org/10.4093/kdj.2010.34.4.222
  • 3,405 View
  • 26 Download
  • 14 Crossref
AbstractAbstract PDFPubReader   
Background

Type 2 diabetes mellitus (T2DM) has a strong genetic component, and its prevalence is notably increased in the family members of T2DM patients. However, there are few studies about the family history of T2DM. We carried out this study to assess the influences of family history on clinical characteristics in T2DM patients.

Methods

This is a cross-sectional study involving 651 T2DM patients. Patient history and physical examination were performed and fasting blood was taken. If any first degree relative was diabetic, a family history of diabetes was considered to exist.

Results

Among the total 621 patients, 38.4% had a family history of diabetes. Patients with a family history had a younger age, higher weight, younger age at diagnosis and higher triglyceride level than did those without a family history. Dyslipidemia medication and metabolic syndrome were more prevalent in familial diabetes. Sex, blood pressure, previous treatment for diabetes, HbA1c, C-peptide, total cholesterol, high density lipoprotein cholesterol, and low density lipoprotein cholesterol were not different between familial and non-familial diabetes. Upon multiple linear regression analysis, the family history of diabetes remained significantly associated with serum triglyceride level.

Conclusion

In T2DM patients with a family history of diabetes, the disease tended to develop earlier. Metabolic syndrome and cardiovascular risk factors are more prevalent in familial T2DM than they were in non-familial T2DM. These results support the necessity of earlier screening for diabetes in family members of T2DM patients and more active prevention against cardiovascular disease in T2DM patients with a family history.

Citations

Citations to this article as recorded by  
  • Evolutionary algorithm for the optimization of meal intake and insulin administration in patients with type 2 diabetes
    Eva Gonzalez-Flo, Elaheh Kheirabadi, Carlos Rodriguez-Caso, Javier Macía
    Frontiers in Physiology.2023;[Epub]     CrossRef
  • Role of Cytokines (IL-17 and IL-33), FGF-18, and WNT-5 in the Pathogenesis of Patients with Established Type II Diabetes
    Przha Mohammed, Kawa Amin
    Journal of Zankoy Sulaimani - Part A.2023; 25(2): 11.     CrossRef
  • Cellular Chitchatting: Exploring the Role of Exosomes as Cardiovascular Risk Factors
    Giulia Germena, Laura Cecilia Zelarayán, Rabea Hinkel
    Frontiers in Cell and Developmental Biology.2022;[Epub]     CrossRef
  • Combined associations of family history and self-management with age at diagnosis and cardiometabolic risk in 86,931 patients with type 2 diabetes: Joint Asia Diabetes Evaluation (JADE) Register from 11 countries
    Johnny T. K. Cheung, Eric Lau, Cyrus C. T. Tsui, Edmond L. N. Siu, Naomi K. W. Tse, Nicole Y. L. Hui, Ronald C. W. Ma, Alice P. S. Kong, Amy Fu, Vanessa Lau, Weiping Jia, Wayne H. H. Sheu, Leorino Sobrepena, K. H. Yoon, Alexander T. B. Tan, Yook-Chin Chia
    BMC Medicine.2022;[Epub]     CrossRef
  • Capsaicin, its clinical significance in patients with painful diabetic neuropathy
    Phiwayinkosi V. Dludla, Bongani B. Nkambule, Ilenia Cirilli, Fabio Marcheggiani, Sihle E. Mabhida, Khanyisani Ziqubu, Yonela Ntamo, Babalwa Jack, Tawanda M. Nyambuya, Sidney Hanser, Sithandiwe E. Mazibuko-Mbeje
    Biomedicine & Pharmacotherapy.2022; 153: 113439.     CrossRef
  • Safety profile of sodium glucose co-transporter 2 (SGLT2) inhibitors: A brief summary
    Annamaria Mascolo, Raffaella Di Napoli, Nunzia Balzano, Donato Cappetta, Konrad Urbanek, Antonella De Angelis, Lucia Scisciola, Irene Di Meo, Maria Giuseppa Sullo, Concetta Rafaniello, Liberata Sportiello
    Frontiers in Cardiovascular Medicine.2022;[Epub]     CrossRef
  • Impact of triglycerides and waist circumference on insulin resistance and β-cell function in non-diabetic first-degree relatives of type 2 diabetes
    Fahd Ahmed, Molham AL-Habori, Ebtesam Al-Zabedi, Riyadh Saif-Ali
    BMC Endocrine Disorders.2021;[Epub]     CrossRef
  • Orientin Improves Substrate Utilization and the Expression of Major Genes Involved in Insulin Signaling and Energy Regulation in Cultured Insulin-Resistant Liver Cells
    Sithandiwe E. Mazibuko-Mbeje, Sinenhlanhla X. H. Mthembu, Andani Tshiitamune, Ndivhuwo Muvhulawa, Fikile T. Mthiyane, Khanyisani Ziqubu, Christo J. F. Muller, Phiwayinkosi V. Dludla
    Molecules.2021; 26(20): 6154.     CrossRef
  • Identification of Pre-Diabetic Biomarkers in the Progression of Diabetes Mellitus
    Jae-Ho Lee, Do-Young Kim, Rubee Pantha, Eun-Ho Lee, Jae-Hoon Bae, Eugene Han, Dae-Kyu Song, Taeg Kyu Kwon, Seung-Soon Im
    Biomedicines.2021; 10(1): 72.     CrossRef
  • Shared (epi)genomic background connecting neurodegenerative diseases and type 2 diabetes
    Valerio Caputo, Andrea Termine, Claudia Strafella, Emiliano Giardina, Raffaella Cascella
    World Journal of Diabetes.2020; 11(5): 155.     CrossRef
  • Family history of diabetes in both parents is strongly associated with impaired residual β‐cell function in Japanese type 2 diabetes patients
    Minoru Iwata, Yutaka Kamura, Hisae Honoki, Kaori Kobayashi, Manabu Ishiki, Kunimasa Yagi, Yasuo Fukushima, Atsuko Takano, Hiromi Kato, Shihou Murakami, Kiyohiro Higuchi, Chikaaki Kobashi, Kazuhito Fukuda, Yukiko Koshimizu, Kazuyuki Tobe
    Journal of Diabetes Investigation.2020; 11(3): 564.     CrossRef
  • The relationship between age of onset and risk factors including family history and life style in Korean population with type 2 diabetes mellitus
    Jin-Won Noh, Jin Hee Jung, Jeong Eun Park, Jung Hwa Lee, Kang Hee Sim, Jumin Park, Min Hee Kim, Ki-Bong Yoo
    Journal of Physical Therapy Science.2018; 30(2): 201.     CrossRef
  • Clinical Characteristics of Subjects with Sulfonylurea-Dependent Type 2 Diabetes
    Se Hee Min, Soo Heon Kwak, Young Min Cho, Kyong Soo Park, Hye Seung Jung
    Endocrinology and Metabolism.2015; 30(4): 509.     CrossRef
  • Nutritional Assessment of Type II Diabetic Patients
    El-Sayed H. Bakr
    Pakistan Journal of Nutrition.2015; 14(6): 308.     CrossRef
Metabolic Risk/Epidemiology
A Composite Blood Biomarker Including AKR1B10 and Cytokeratin 18 for Progressive Types of Nonalcoholic Fatty Liver Disease
Seung Joon Choi, Sungjin Yoon, Kyoung-Kon Kim, Doojin Kim, Hye Eun Lee, Kwang Gi Kim, Seung Kak Shin, Ie Byung Park, Seong Min Kim, Dae Ho Lee
Received June 18, 2023  Accepted August 16, 2023  Published online February 1, 2024  
DOI: https://doi.org/10.4093/dmj.2023.0189    [Epub ahead of print]
  • 637 View
  • 33 Download
AbstractAbstract PDFSupplementary MaterialPubReader   ePub   
Background
We aimed to evaluate whether composite blood biomarkers including aldo-keto reductase family 1 member B10 (AKR1B10) and cytokeratin 18 (CK-18; a nonalcoholic steatohepatitis [NASH] marker) have clinically applicable performance for the diagnosis of NASH, advanced liver fibrosis, and high-risk NASH (NASH+significant fibrosis).
Methods
A total of 116 subjects including healthy control subjects and patients with biopsy-proven nonalcoholic fatty liver disease (NAFLD) were analyzed to assess composite blood-based and imaging-based biomarkers either singly or in combination.
Results
A composite blood biomarker comprised of AKR1B10, CK-18, aspartate aminotransferase (AST), and alanine aminotransferase (ALT) showed excellent performance for the diagnosis of, NASH, advanced fibrosis, and high-risk NASH, with area under the receiver operating characteristic curve values of 0.934 (95% confidence interval [CI], 0.888 to 0.981), 0.902 (95% CI, 0.832 to 0.971), and 0.918 (95% CI, 0.862 to 0.974), respectively. However, the performance of this blood composite biomarker was inferior to that various magnetic resonance (MR)-based composite biomarkers, such as proton density fat fraction/MR elastography- liver stiffness measurement (MRE-LSM)/ALT/AST for NASH, MRE-LSM+fibrosis-4 index for advanced fibrosis, and the known MR imaging-AST (MAST) score for high-risk NASH.
Conclusion
Our blood composite biomarker can be useful to distinguish progressive forms of NAFLD as an initial noninvasive test when MR-based tools are not available.

Diabetes Metab J : Diabetes & Metabolism Journal